Table 3.

In vivo efficacy of fotemustine and temozolomide in the four human melanoma xenografts tested

ModelsTreatmentsGDI (d)TGI (%)CR/total mice (%)Median CR duration (d)
MP77Fotemustine13.8100 (15)8/9 (89)58
Temozolomide21.397 (14)7/8 (87)36
MP38Fotemustine>3.75100 (73)7/9 (66)(>48-30)
Temozolomide>297 (66)0/9 (0)
MM26Fotemustine2.886 (44)0/8 (0)
Temozolomide5.195 (59)0/10 (0)
MM66Fotemustine1.265 (49)0/8 (0)
Temozolomide1.886 (15)2/6 (33)5

Abbreviations: GDI, growth delay inhibition defined as the time required to reach the same RTV in the treated group and the control group (usually at a RTV of 4); CR, complete remission.